Emerging drugs in metastatic breast cancer

about

S100P: a novel therapeutic target for cancer.Theranostic imaging of cancer.ErbB2 activation upregulates glutaminase 1 expression which promotes breast cancer cell proliferation

P2860

Q33699305-CF72B781-A78B-485A-8B44-FA2E4360CD16 Q33791349-A8FE2657-4060-4EB8-A0F6-64A436900214 Q35899955-4F88E653-E544-41CA-A4E2-72F948599918

P2860

Emerging drugs in metastatic breast cancer

Item

http://www.wikidata.org/entity/Q57142532

description

im März 2009 veröffentlichter wissenschaftlicher Artikel

@de

wetenschappelijk artikel

@nl

наукова стаття, опублікована в березні 2009

@uk

name

Emerging drugs in metastatic breast cancer

@en

Emerging drugs in metastatic breast cancer

@nl

type

Item

label

Emerging drugs in metastatic breast cancer

@en

Emerging drugs in metastatic breast cancer

@nl

prefLabel

Emerging drugs in metastatic breast cancer

@en

Emerging drugs in metastatic breast cancer

@nl

P1476

Emerging drugs in metastatic breast cancer

@en

P2093

Kadri Altundag

http://www.w3.org/2001/XMLSchema#string

Omer Dizdar

http://www.w3.org/2001/XMLSchema#string

P2860

Estrogen as therapy for breast cancer.

Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2.

Randomized phase II trial of the efficacy and safety of trastuzumab combined with docetaxel in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer administered as first-line treatment: the M77001 study group.

Lapatinib plus capecitabine for HER2-positive advanced breast cancer.

Cancer statistics, 2008

Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene

A phase I/II dose-escalation trial of bevacizumab in previously treated metastatic breast cancer

Arterial thromboembolic events in patients with metastatic carcinoma treated with chemotherapy and bevacizumab

Ixabepilone plus capecitabine for metastatic breast cancer progressing after anthracycline and taxane treatment

A randomized comparison of single-agent doxorubicin and epirubicin as first-line cytotoxic therapy in advanced breast cancer

P304

85-98

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1517/14728210802625671

http://www.w3.org/2001/XMLSchema#string

P407

English

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2009-03-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

19278368

http://www.w3.org/2001/XMLSchema#string

Emerging drugs in metastatic breast cancer

about

P2860

P2860

Emerging drugs in metastatic breast cancer

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P407

P433

P478

P577

P698

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P407

P433

P478

P577

P698